Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 778

The DOI matches its Crossref record; 671 of the 671 references it cites were found in a registry or an index.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets

Open access
Feitelson, Mark A., Arzumanyan, Alla, Kulathinal, Rob J., Blain, Stacy W., Holcombe, Randall F., Mahajna, Jamal, Marino, Maria, Martinez-Chantar, Maria L., Nawroth, Roman, Sanchez-Garcia, Isidro, Sharma, Dipali, Saxena, Neeraj K., Singh, Neetu, Vlachostergios, Panagiotis J., Guo, Shanchun, Honoki, Kanya, Fujii, Hiromasa, Georgakilas, Alexandros G., Bilsland, Alan, Amedei, Amedeo, Niccolai, Elena, Amin, Amr, Ashraf, S. Salman, Boosani, Chandra S., Guha, Gunjan, Ciriolo, Maria Rosa, Aquilano, Katia, Chen, Sophie, Mohammed, Sulma I., Azmi, Asfar S., Bhakta, Dipita, Halicka, Dorota, Keith, W. Nicol, Nowsheen, Somaira·2015·Seminars in Cancer Biology

Abstract

Proliferation is an important part of cancer development and progression. This is manifest by altered expression and/or activity of cell cycle related proteins. Constitutive activation of many signal transduction pathways also stimulates cell growth. Early steps in tumor development are associated with a fibrogenic response and the development of a hypoxic environment which favors the survival and proliferation of cancer stem cells. Part of the survival strategy of cancer stem cells may manifested by alterations in cell metabolism. Once tumors appear, growth and metastasis may be supported by overproduction of appropriate hormones (in hormonally dependent cancers), by promoting angiogenesis, by undergoing epithelial to mesenchymal transition, by triggering autophagy, and by taking cues from surrounding stromal cells. A number of natural compounds (e.g., curcumin, resveratrol, indole-3-carbinol, brassinin, sulforaphane, epigallocatechin-3-gallate, genistein, ellagitannins, lycopene and quercetin) have been found to inhibit one or more pathways that contribute to proliferation (e.g., hypoxia inducible factor 1, nuclear factor kappa B, phosphoinositide 3 kinase/Akt, insulin-like growth factor receptor 1, Wnt, cell cycle associated proteins, as well as androgen and estrogen receptor signaling). These data, in combination with bioinformatics analyses, will be very important for identifying signaling pathways and molecular targets that may provide early diagnostic markers and/or critical targets for the development of new drugs or drug combinations that block tumor formation and progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2015.02.006

Cites

671 of 671 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

7 retracted

Research works printed but not linked: 51

  1. Wang, 2013, SLUG is activated by nuclear factor kappa B and confers human alveolar epithelial A549 cells resistance to tumor necrosis factor-alpha-induced apoptosis, World J Surg Oncol, 11, 12, 10.1186/1477-7819-11-12 · doi:10.1186/1477-7819-11-12
  2. Hede, 2006, PTEN takes center stage in cancer stem cell research, works as tumor suppressor, J Natl Cancer Inst, 98, 808, 10.1093/jnci/djj270 · doi:10.1093/jnci/djj270
  3. Hamburger, 1977, Primary bioassay of human myeloma stem cells, J Clin Invest, 60, 846, 10.1172/JCI108839 · doi:10.1172/jci108839
  4. Sánchez-García, 2009, The crossroads of oncogenesis and metastasis, N Engl J Med, 360, 297, 10.1056/NEJMcibr0808031 · doi:10.1056/nejmcibr0808031
  5. Tomellini, 2014, NGF and proNGF simultaneously promote symmetric self-renewal, quiescence and EMT to enlarge the breast cancer stem cell compartment, Stem Cells
  6. Tamari, 2014, Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity, Int J Oncol, 45, 2349, 10.3892/ijo.2014.2671 · doi:10.3892/ijo.2014.2671
  7. Krishnan, 2013, Using MKK4's metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization, Cancer Metastasis Rev, 31, 605, 10.1007/s10555-012-9371-y · doi:10.1007/s10555-012-9371-y
  8. Fang, 2011, Imatinib plus granulocyte colony-stimulating factor in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response while on Imatinib, Case Rep Oncol, 4, 192, 10.1159/000327512 · doi:10.1159/000327512
  9. Danovi, 2008, Angiogenesis: turning it down a Notch, Nat Rev Cancer, 8, 572, 10.1038/nrc2448 · doi:10.1038/nrc2448
  10. Kakarala, 2007, Cancer stem cells: implications for cancer treatment and prevention, Cancer J, 13, 271, 10.1097/PPO.0b013e318156da4e · doi:10.1097/ppo.0b013e318156da4e
  11. Chen, 1997, Regulation of the ERBB-2 promoter by RBPJк and NOTCH, J Biol Chem, 272, 14110, 10.1074/jbc.272.22.14110 · doi:10.1074/jbc.272.22.14110
  12. Ghayad, 2010, Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients, Recent Pat Anticancer Drug Discov, 5, 29, 10.2174/157489210789702208 · doi:10.2174/157489210789702208
  13. Jeng, 2012, Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: an in vivo study, Oncology Lett, 4, 1158, 10.3892/ol.2012.935 · doi:10.3892/ol.2012.935
  14. Kinsell, 1948, Studies in methionine and sulfur metabolism. I. The fate of intravenously administered methionine in normal individuals and in patients with liver damage, J Clin Invest, 27, 677, 10.1172/JCI102016 · doi:10.1172/jci102016
  15. Mintz, 2008, The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer, Cancer, 113, 1489, 10.1002/cncr.23699 · doi:10.1002/cncr.23699
  16. Bolli, 2011, Current and future development of estrogen receptor ligands: applications in estrogen-related cancers, Recent Pat Endocr Metab Immune Drug Discov, 5, 210, 10.2174/187221411797265881 · doi:10.2174/187221411797265881
  17. Pedersen, 2005, Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII, Br J Cancer, 93, 915, 10.1038/sj.bjc.6602793 · doi:10.1038/sj.bjc.6602793
  18. Kuhad, 2007, Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity, J Agric Food Chem, 55, 10150, 10.1021/jf0723965 · doi:10.1021/jf0723965
  19. Izutani, 2012, Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells, Int J Oncol, 40, 816
  20. Wen, 2010, Preparation and physicochemical properties of the complex of naringenin with hydroxypropyl-β-cyclodextrin, Molecules, 15, 4401, 10.3390/molecules15064401 · doi:10.3390/molecules15064401
  21. Choi, 2004, Kim YC Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin, Eur J Pharm Biopharm, 57, 313, 10.1016/j.ejpb.2003.11.002 · doi:10.1016/j.ejpb.2003.11.002
  22. Kanadzu, 2006, Dual function of epigallocatechin gallate (EGCG) in healthy human lymphocytes, Cancer Lett, 241, 250, 10.1016/j.canlet.2005.10.021 · doi:10.1016/j.canlet.2005.10.021
  23. Parker, 2009, Modulation of microRNA associated with ovarian cancer cells by genistein, Eur J Gynaecol Oncol, 30, 616
  24. Park, 2010, Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma, Cancer Lett, 292, 54, 10.1016/j.canlet.2009.11.004 · doi:10.1016/j.canlet.2009.11.004
  25. Mills, 1989, Cohort study of diet, lifestyle, and prostate cancer in Adventist men, Cancer, 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 · doi:10.1002/1097-0142(19890801)64:3<598::aid-cncr2820640306>3.0.co;2-6
  26. Giovannucci, 2007, Does prostate-specific antigen screening influence the results of studies of tomatoes, lycopene, and prostate cancer risk?, J Natl Cancer Inst, 99, 1060, 10.1093/jnci/djm048 · doi:10.1093/jnci/djm048
  27. Choi, 2004, Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin, Eur J Pharm Biopharm, 57, 313, 10.1016/j.ejpb.2003.11.002 · doi:10.1016/j.ejpb.2003.11.002
  28. Guruvayoorappan, 2008, 13 cis-retinoic acid regulates cytokine production and inhibits angiogenesis by disrupting endothelial cell migration and tube formation, J Exp Ther Oncol, 7, 173
  29. Zaidman, 2008, Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells, Mol Biol Rep, 35, 107, 10.1007/s11033-007-9059-5 · doi:10.1007/s11033-007-9059-5
  30. Zhang, 2011, Genistein attenuates WNT signaling by up-regulating sFRP2 in a human colon cancer cell line, Exp Biol Med (Maywood), 236, 714, 10.1258/ebm.2011.010347 · DOI
  31. Abdelwahab, 2011, Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells, Leuk Res, 35, 268, 10.1016/j.leukres.2010.07.025 · doi:10.1016/j.leukres.2010.07.025
  32. Tang, 2010, (−)-Epigallocatechin3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells, J Cancer Res Clin Oncol, 136, 1179, 10.1007/s00432-010-0765-3 · doi:10.1007/s00432-010-0765-3
  33. Cheng, 2011, Novel agents for the treatment of pancreatic adenocarcinoma, JOP, 12, 334
  34. Huynh, 2003, Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation, Int J Oncol, 23, 821
  35. Pratheeshkumar, 2012, Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways, PLoS ONE, 7, e47516, 10.1371/journal.pone.0047516 · DOI · Paper page
  36. Chen, 2013, Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells, FEBS Lett, 587, 3327, 10.1016/j.febslet.2013.08.022 · doi:10.1016/j.febslet.2013.08.022
  37. Gabellini, 2013, BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition, Carcinogenesis, 34, 2558, 10.1093/carcin/bgt242 · doi:10.1093/carcin/bgt242
  38. Wang, 2013, Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis, Oncotarget, 4, 1158, 10.18632/oncotarget.1093 · doi:10.18632/oncotarget.1093
  39. Nishinakagawa, 2010, Analysis of cell cycle arrest and apoptosis induced by RCAS1, Int J Mol Med, 25, 717
  40. Wong, 2009, Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages, Cancer Lett, 276, 38, 10.1016/j.canlet.2008.10.025 · doi:10.1016/j.canlet.2008.10.025
  41. Maeyama, 2011, Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region, Int J Oncol, 39, 41
  42. Peretz, 2002, IGF1 receptor expression protects against microenvironmental stress found in the solid tumor, Radiat Res, 158, 174, 10.1667/0033-7587(2002)158[0174:IREPAM]2.0.CO;2 · doi:10.1667/0033-7587(2002)158[0174:irepam]2.0.co;2
  43. Dorai, 2000, Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen independent prostate cancer cells, Prostate Cancer Prostatic Dis, 3, 84, 10.1038/sj.pcan.4500399 · doi:10.1038/sj.pcan.4500399
  44. Park, 2002, Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53, Int J Oncol, 21, 379
  45. Nakamura, 2012, Genistein inhibits cell invasion and motility by inducing cell differentiation in murine osteosarcoma cell line LM8, BMC Cell Biol, 13, 24, 10.1186/1471-2121-13-24 · doi:10.1186/1471-2121-13-24
  46. Yu, 2011, Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor, Oncol Rep, 26, 1197
  47. Chen, 2011, Anti-proliferative and anti-metastatic effects of curcumin on oral cancer cells, Hua Xi Kou Qiang Yi Xue Za Zhi, 29, 83
  48. Mendivil, 2011, AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways, Reprod Sci, 18, 832, 10.1177/1933719111398501 · doi:10.1177/1933719111398501
  49. Sayeed, 2013, Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells, PLoS ONE, 8, e67191, 10.1371/journal.pone.0067191 · doi:10.1371/journal.pone.0067191
  50. Breen, 2013, Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors, PLoS ONE, 8, e72407, 10.1371/journal.pone.0072407 · doi:10.1371/journal.pone.0072407
  51. Bryant, 2010, Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression, Arch Gynecol Obstet, 282, 677, 10.1007/s00404-010-1381-9 · doi:10.1007/s00404-010-1381-9

Cited by

See all 778

Metadata

Authors
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., Sharma, D., Saxena, N. K., Singh, N., Vlachostergios, P. J., Guo, S., Honoki, K., Fujii, H., Georgakilas, A. G., Bilsland, A., Amedei, A., Niccolai, E., Amin, A., Ashraf, S. S., Boosani, C. S., Guha, G., Ciriolo, M. R., Aquilano, K., Chen, S., Mohammed, S. I., Azmi, A. S., Bhakta, D., Halicka, D., Keith, W. N., & Nowsheen, S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2015-12
Volume
35
Pages
S25-S54
ISSN
1044-579X (ISSN-L)
OpenAlex
W2026982091
Cited by
778
References
671
FWCI
10.66
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • European Commission (MC-CIG-303514)
  • Associazione Italiana per la Ricerca sul Cancro (IG15221, 10636)
  • National Institutes of Health (AI076535)
  • University of Glasgow
  • National Science Foundation
  • Purdue University Center for Cancer Research
  • Avon Foundation for Women
  • Cancer Research UK (C301/A14762)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (20125S38FA_002)
  • European Cooperation in Science and Technology (CM1201)
  • Ministero della Salute (GR-2011-02348047)
  • Breast Cancer Research Foundation (K01DK077137, 90047965, R03DK089130, SR/FT/LS-063/2008)
  • Seventh Framework Programme (CA155686, R01CA131294)
  • Al Jalila Foundation (AJF201454)
  • Ministry of Education, Culture, Sports, Science and Technology (24590493)
  • European Regional Development Fund
  • Ministerio de Ciencia e Innovación (SAF2012-32810, R01 CA109335-04A1)
  • Università degli Studi Roma Tre (CLA 2013)
  • Consejería de Educación, Junta de Castilla y León (BIO/SA06/13, FP7-ENV-2011)
  • American Cancer Society
  • Temple University
  • Terry Fox Foundation (TF-36)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.